Quetiapine: A review of its use in schizophrenia

CNS Drugs

Volumn 9, Issue 4, 1998, Pages 325-340

  Gunasekara, Nishan S ^a   Spencer, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; QUETIAPINE;

CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; TACHYCARDIA; XEROSTOMIA;

EID: 0031953821     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199809040-00007     Document Type: Review

References (43)

1. Fulton B, Goa KL. ICI-204,636: an initial appraisal of its pharmacological properties and clinical potential in the treatment of schizophrenia. CNS Drugs 1995 Jul; 4: 68-78
2. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993 Sep; 112: 285-92
3. Richelson E, Souder T, Acuna J, et al. Binding studies with some new neuroleptics at human brain receptors [abstract]. Biol Psychiatry 1997; 41 Suppl. 7: 67S-8S
4. Küfferle B, Tauscher J, Asenbaum S, et al. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology 1997; 133: 323-8
5. Gefvert O, Lindstrom LH, Langstrom B, et al. Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150mg 'Seroquel' tid [abstract]. Eur Neuropsychopharmacol 1995 Sep; 5 Spec Issue: 347
6. Goldstein JM, Litwin LC, Sutton EB, et al. Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology 1993 Sep; 112: 293-8
7. Skarsfeldt T. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 1995 Aug 15; 281: 289-94
8. Vahid-Ansari F, Nakabeppu Y, Robertson GS. Contrasting effects of chronic clozapine, Seroquel (ICI 204,636) and haloperidol administration on ΔfosB-like immunoreactivity in the rodent forebrain. Eur J Neurosci 1996 May; 8: 927-36
9. Migler BM, Warawa EJ, Malick JB. Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology 1993 Sep; 112: 299-307
10. Ellenbroek BA, Lubbers LJ, Cools AR. Activity of 'Seroquel' (ICI 204,636) in animal models for atypical properties of antipsychotics: a comparison with clozapine. Neuropsychopharmacology 1996 Oct; 15: 406-16
11. Fleming K, Kalali A, Yeh C, et al. The neurocognitive effects of quetiapine ('Seroquel', ICI 204,636) [abstract]. Schizophr Res 1997; 24 (1 Pt 2): 197
12. Hamner MB, Arvanitis LA, Miller BG, et al. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636). Psychopharmacol Bull 1996; 32 (1): 107-10
13. Borison RI, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996 Apr; 16: 158-69
14. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997 Oct; 96: 265-73
15. Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997 Aug 15; 42: 233-46
16. Thyrum PT, Fabre LF, Wong YWJ. Multiple-dose pharmacokinetics of ICI 204,636 in schizophrenic men and women [abstract]. Psychopharmacol Bull 1996; 32 (3): 525
17. Zeneca. Professional Information Brochure: Seroquel (quetiapine fumarate) tablets. Delaware, USA, 1997
18. Grimm SW, Stams KR, Bui K. In vitro prediction of potential metabolic drug interactions for Seroquel [abstract]. Schizophr Res 1997; 24 (1/2): 198
19. Thyrum PT, Jaskiw G, Fuller M, et al. Multiple-dose pharmacokinetics of ICI 204,636 in elderly patients with selected psychotic disorders [abstract]. Psychopharmacol Bull 1996; 32 (3): 524
20. Wong YWJ, Ewing BJ, Thyrum PT, et al. Pharmacokinetics of 'Seroquel' (quetiapine) in hepatic and renal insufficiency [abstract]. Schizophr Res 1997; 24 (1/2): 200
21. Wong J, Ewing B, Thyrum P, et al. Kinetics of 'Seroquel' in hepatic and renal insufficiency. Presented at the 10th World Congress of Psychiatry: 1996 Aug 23-8; Madrid
22. Wong YWJ, Ewing BJ, Thyrum PT, et al. The effect of phenytoin and cimetidine on the pharmacokinetics of seroquel [abstract]. Schizophr Res 1997; 24 (1 Pt 2): 200-1
23. Zeneca. Quetiapine combined summary of product characteristics. Cheshire, UK, 1997
24. Potkin SG, Thyrum PT, Bera R, et al. Pharmacokinetics and safety of lithium coadministered with 'Seroquel' (quetiapine). Schizophr Res 1997; 24 (1/2): 199
25. Wong YWJ, Ewing BJ, Thyrum PT, et al. Effects of haloperidol, risperidone, and thioridazine on the pharmacokinetics of quetiapine [abstract]. Psychopharmacol Bull 1997; 33 (3): 605
26. American Psychiatric Association Task Force on Nomenclature and Statistics. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: APA Press, 1987
27. King DJ, Link CGG, Kowalcyk B. A comparison of bd and tid dose regimens of quetiapine ('Seroquel') in the treatment of schizophrenia. Psychopharmacology. In press
28. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997 Jun; 54: 549-57
29. Fabre Jr LF, Arvanitis L, Pultz J, et al. ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995 May-Jun; 17: 366-78
30. Meats P. Quetiapine ('Seroquel'): an effective and well-tolerated atypical antipsychotic. Int J Psychiatry Clin Prac 1997; 1 (4): 231-9
31. Arvanitis LA, Rak IW. The long-term efficacy and safety of 'Seroquel' (quetiapine) [abstract]. Schizophr Res 1997; 24 (1/2): 196-7
32. Casey DE. Seroquel (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Expert Opin Invest Drug 1996 Aug; 5: 939-57
33. Zeneca. Seroquel (quetiapine) prescribing information. Ontario, Canada, 1997
34. Goldstein JM, Arvanitis LA, CAntillon M. Low incidence of reproductive/hormonal side effects with 'Seroquel' (quetiapine fumarate) is supported by its lack of elevation of plasma prolactin concentrations. Proceedings of the American College or Neuropsychopharmacology: 1997 Dec; Hawaii
35. Arvanitis LA, Rak IW. Efficacy, safety and tolerability of 'Seroquel' (quetiapine) in elderly subjects with psychotic disorders [abstract]. Schizophr Res 1997; 24 (1/2): 196
36. Kalali AH, Langham SJ, Hurst BC, et al. Long term treatment with 'Seroquel': interim results of a multinational study of patient satisfaction and acceptability [poster]. 9th Biennial Winter Workshop on Schizophrenia: 1998; Davos
37. Carpenter Jr WT, Buchanan RW. Schizophrenia. N Engl J Med 1994; 330 (10): 681-90
38. Terkelsen KG, Menikoff A. Measuring the costs of schizophrenia. Pharmacoeconomics 1995; 8 (3): 199-222
39. Davis JM, Schaffer CB, Killman GA, et al. Important issues in the treatment of schizophrenia. Schizophr Bull 1980 (6): 70-87
40. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 1996; 57 Suppl. 11: 68-71
41. Kerwin R Taylor D. New antipsychotics: a review of their current status and clinical potential. CNS Drugs 1996 Jul; 6: 71-82
42. Meltzer HY. Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br J Psychiatry 1996; 168 Suppl. 29: 23-31
43. Wagstaff AJ, Bryson HM. Clozapine: a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 1995; 4 (5): 370-400